LM-030

LM-030 is an investigational small molecule drug developed as a topical therapy for Netherton syndrome, a rare and severe autosomal recessive skin disorder characterized by congenital erythroderma, “bamboo hair,” and immune system abnormalities. The drug acts as an inhibitor of kallikrein-related peptidase 7 (KLK7) and epidermal elastase 2 (ELA2), enzymes implicated in the pathogenesis of Netherton syndrome. By inhibiting these proteases, LM-030 aims to restore skin barrier function and reduce inflammation. It has received orphan drug designation, fast track designation, and rare pediatric disease designation from the FDA due to its potential to address this life-threatening condition with no currently approved therapies[2][4][5][6][8].